Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of zibotentan and dapagliflozin on albuminuria in patients with elevated albuminuria
2021-001324-18Phase 2Completed
- Sponsor
- University Medical Center Groningen
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of zibotentan and dapagliflozin in diabetic glomerulosclerosis and chronic kidney disease (CKD) (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Change in albuminuria (geometric mean ratio of albumin:creatinine). Started Jun 2021; status: completed.
02
Drugs
zibotentandapagliflozin
03
Conditions
diabetic glomerulosclerosischronic kidney disease (CKD)
Beyond the preview
Go deeper on 2021-001324-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001324-18.